Catalyst Event

Johnson & Johnson (JNJ) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/13/2026, 12:00:00 AM

OtherSentiment: Positive

Announced positive results from the Phase 3 MonumenTAL-3 study of TALVEY® on 2026-06-13 and submitted for regulatory approval; the clinical success is estimated to have a 2% price impact.

Korean Translation

2026년 6월 13일, TALVEY®의 3상 MonumenTAL-3 연구에서 긍정적인 결과를 발표하고 규제 승인을 신청함. 이는 약 2%의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline